Genocea Biosciences, Inc. (GNCA)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (0.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.70 USD
+0.01 (0.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for Genocea (GNCA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
by Zacks Equity Research
Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Genocea Biosciences (GNCA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 13th
by Zacks Equity Research
ASC, BCEI, XOG, GNCA, and GNLN have been added to the Zacks Rank #5 (Strong Sell) List on April 13, 2021
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Is Genocea Biosciences (GNCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GNCA) Outperforming Other Medical Stocks This Year?
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
by Zacks Equity Research
Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
New Strong Buy Stocks for April 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Genocea Biosciences, Inc. (GNCA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).
Genocea Biosciences Enters Oversold Territory
by Zacks Equity Research
Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for March 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th
Will Genocea Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences.
Top Ranked Momentum Stocks to Buy for March 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th
Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Genocea Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
by Zacks Equity Research
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors in Genocea Biosciences (GNCA) need to pay close attention to the stock based on moves in the options market lately.
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%
by Zacks Equity Research
GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.
Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher
by Zacks Equity Research
Genocea Biosciences, Inc. (GNCA) shares rose almost 12% in the last trading session.
Should You Sell Genocea Biosciences (GNCA) Before Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Genocea Biosciences, Inc. (GNCA) may be one such company.